uniQure(US:QURE) TMX Newsfile·2026-02-11 20:41Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. on behalf of investors who acquired its securities during the specified class period, alleging misrepresentation and failure to disclose critical information regarding the company's drug development process [1][3]. Company Overview - uniQure N.V. is a biotechnology company based in Amsterdam, focusing on gene therapies for severe diseases, including Huntington's disease [2]. Legal Allegations - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study for the drug AMT-130 and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline due to the need for additional studies [3]. Stock Impact - Following the disclosure that the FDA did not agree with the use of Phase I/II data for BLA submission, uniQure's stock price plummeted over 49%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [4].